Antoine Yver (L) and Saurabh Saha

Ahead of Nas­daq de­but, Saurabh Sa­ha pads out the C-suite at Centes­sa, hir­ing a top Dai­ichi Sankyo alum as CMO

Centes­sa is wast­ing no time as­sem­bling the top team in charge of spear­head­ing its port­fo­lio play.

While pre­sum­ably go­ing on vir­tu­al road­shows for its up­com­ing IPO, the biotech put out word that it’s ap­point­ed An­toine Yver, the for­mer head of on­col­o­gy R&D at Dai­ichi Sankyo, as CMO.

With 16 pro­grams in the pipeline — four of which have al­ready reached clin­i­cal stage — that came to­geth­er af­ter Francesco De Ru­ber­tis con­vinced 11 Medicxi star­tups to roll their op­er­a­tions in­to the same com­pa­ny, Yver is sure to hit the ground run­ning. CEO Saurabh Sa­ha clear­ly has no doubt about that, prais­ing his new de­vel­op­ment chief as a “true in­dus­try leader.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.